Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 164Lung Neoplasms 61Small Cell Lung Carcinoma 24Neoplasms 10NSCLC 9Mesothelioma, Malignant 9Breast Neoplasms 8Pancreatic Neoplasms 7Ovarian Neoplasms 7Melanoma 6Head and Neck Neoplasms 6Colorectal Neoplasms 6Esophageal Neoplasms 5Stomach Neoplasms 4Neoplasm Metastasis 4Mesothelioma 4Kidney Neoplasms 4Brain Neoplasms 4Sarcoma 3Pleural Effusion, Malignant 3Liver Neoplasms 3Fallopian Tube Neoplasms 3Cholangiocarcinoma 3Carcinoma 3Adenocarcinoma of Lung 3Uterine Cervical Neoplasms 2Thymus Neoplasms 2Thymoma 2Small Cell Lung Cancer Limited Stage 2Skin Neoplasms 2

Interventions

pembrolizumab 4Pemetrexed 4Carboplatin 4Gemcitabine 3Bevacizumab 3tusamitamab ravtansine 2Vinorelbine 2Ramucirumab 2Erlotinib Hydrochloride 2Docetaxel 21-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 2vistusertib 1vandetanib 1telomerase reverse transcriptase p572Y, human 1spartalizumab 1sotorasib 1sintilimab 1olaparib 1necitumumab 1icotinib 1durvalumab 1dacomitinib 1capivasertib 1aumolertinib 1Radiosurgery 1Platinum 1Paclitaxel 1MLN 8237 1LY3023414 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non-small Cell Lung Cancer Metastatic × Drug Therapy × Thoracic × Clear all
NCT03656094 2019-12-09

Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors

Samsung Medical Center

Phase 2 Unknown
98 enrolled
Thoracic

Non-small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡